# A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

> **NCT06538116** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 300 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Mevidalen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06538116
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538116, "A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06538116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*